Patents by Inventor Jong-Yuh Cherng

Jong-Yuh Cherng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8962587
    Abstract: The present invention provides a method for decreasing the level of methylation of Oct4 promoter in a target cell, comprising transfecting the target cell with the combination of Oct4 cDNA and SirT1 cDNA. The invention also provides a method for inducing cytoprotective responses of a target cell, comprising transfecting the target cell with the combination of Oct4 cDNA and SirT1 cDNA. The invention further provides a pharmaceutical composition comprising Oct4 cDNA and SirT1 cDNA, or a polynucleotide comprising Oct4 cDNA and SirT1 cDNA.
    Type: Grant
    Filed: August 31, 2012
    Date of Patent: February 24, 2015
    Assignee: Taipei Veterans General Hospital
    Inventors: Shih-Hwa Chiou, Jong-Yuh Cherng
  • Patent number: 8846633
    Abstract: The present invention provides a method for inhibiting cancer stem cell like properties and chemoradioresistant properties of cancer or tumor cells comprising delivering miR145 to the cancer or tumor cells, particularly brain tumor and head and neck cancer cells. The invention further provides a pharmaceutical composition comprising miR145 and a method for treating brain tumor and/or head and neck cancer comprising administration of miR145 to a subject in need thereof.
    Type: Grant
    Filed: November 7, 2012
    Date of Patent: September 30, 2014
    Assignee: Taipei Veterans General Hospital
    Inventors: Shih-Hwa Chiou, Han-Shui Hsu, Jong-Yuh Cherng
  • Publication number: 20130052238
    Abstract: The present invention provides a method for decreasing the level of methylation of Oct4 promoter in a target cell, comprising transfecting the target cell with the combination of Oct4 cDNA and SirT1 cDNA. The invention also provides a method for inducing cytoprotective responses of a target cell, comprising transfecting the target cell with the combination of Oct4 cDNA and SirT1 cDNA. The invention further provides a pharmaceutical composition comprising Oct4 cDNA and SirT1 cDNA, or a polynucleotide comprising Oct4 cDNA and SirT1 cDNA.
    Type: Application
    Filed: August 31, 2012
    Publication date: February 28, 2013
    Applicant: TAIPEI VETERANS GENERAL HOSPITAL
    Inventors: Shih-Hwa Chiou, Jong-Yuh Cherng
  • Patent number: 7179874
    Abstract: A biodegradable cationic polymer is disclosed. The biodegradable cationic polymer of the invention has amino groups in the backbone and side chains, self-assembles cationic complexes with nucleic acids, and delivers nucleic acids into a cell by endocytosis. The biodegradable cationic polymer of the invention also has very low cytotoxicity. Methods of making and using the biodegradable cationic polymer are further disclosed.
    Type: Grant
    Filed: November 21, 2003
    Date of Patent: February 20, 2007
    Assignee: Chia Nan University of Pharmacy and Science
    Inventors: Min-Da Shau, Jong-Yuh Cherng, Tsung-Fu Yang, Wei-Kuo Chin
  • Publication number: 20050112203
    Abstract: A biodegradable cationic polymer is disclosed. The biodegradable cationic polymer of the invention has amino groups in the backbone and side chains, self-assembles cationic complexes with nucleic acids, and delivers nucleic acids into a cell by endocytosis. The biodegradable cationic polymer of the invention also has very low cytotoxicity. Methods of making and using the biodegradable cationic polymer are further disclosed.
    Type: Application
    Filed: November 21, 2003
    Publication date: May 26, 2005
    Inventors: Min-Da Shau, Jong-Yuh Cherng, Tsung-Fu Yang, Wei-Kuo Chin